Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.170
-0.060 (-4.88%)
At close: Mar 27, 2026, 4:00 PM EDT
1.160
-0.010 (-0.85%)
After-hours: Mar 27, 2026, 6:36 PM EDT
Pliant Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
49
Market Cap
72.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.58M | -8.11M | -83.69% |
| Dec 31, 2022 | 9.69M | 2.11M | 27.91% |
| Dec 31, 2021 | 7.57M | -34.25M | -81.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 35.58M |
| Pelthos Therapeutics | 16.80M |
| NeurAxis | 3.57M |
| NRx Pharmaceuticals | 1.23M |
| MediciNova | 409.66K |
| aTyr Pharma | 190.00K |
| Fractyl Health | 3.00K |
PLRX News
- 11 days ago - Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - GlobeNewsWire
- 18 days ago - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - GlobeNewsWire
- 23 days ago - Stock Picks From Seeking Alpha's February 2026 New Analysts - Seeking Alpha
- 4 weeks ago - Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha
- 4 weeks ago - Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - GlobeNewsWire
- 4 months ago - Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors - Benzinga
- 4 months ago - Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - GlobeNewsWire
- 4 months ago - Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - GlobeNewsWire